Cetuximab + Irinotecan + IMC-A12 (cixutumumab)

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Colon Cancer

Conditions

Colon Cancer, Rectal Cancer

Trial Timeline

May 1, 2009 → Feb 1, 2011

NCT ID

NCT00845039

About Cetuximab + Irinotecan + IMC-A12 (cixutumumab)

Cetuximab + Irinotecan + IMC-A12 (cixutumumab) is a phase 2 stage product being developed by Eli Lilly for Colon Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00845039. Target conditions include Colon Cancer, Rectal Cancer.

What happened to similar drugs?

4 of 14 similar drugs in Colon Cancer were approved

Approved (4) Terminated (5) Active (6)

🔄fospropofol disodiumEisaiPhase 3

🔄Calderasib + Oxaliplatin + Leucovorin/levofolinate calcium + 5-Fluorouracil + Cetuximab + Bevacizumab + Bevacizumab biosimilarMerckPhase 3

❌AvelumabMerckPhase 3

🔄Systemic treatmentRochePhase 3

❌AZLI + PlaceboGilead SciencesPhase 3

🔄Isovorin + UFTPfizerPhase 3

✅Methylnaltrexone Bromide (MNTX) + PlaceboPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00845039	Phase 2	Terminated	May 1, 2009	Feb 1, 2011	Colon Cancer

Competing Products

20 competing products in Colon Cancer

See all competitors

Product	Company	Stage	Hype Score
FOLFIRI + E7820	Eisai	Phase 1/2	24
fospropofol disodium	Eisai	Phase 3	40
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCl	Eisai	Phase 2/3	38
fospropofol disodium	Eisai	Phase 2	27
fospropofol disodium	Eisai	Phase 2	35
Ramucirumab + Icrucumab + mFOLFOX-6	Eli Lilly	Phase 2	35
Vinorelbine Tartrate	Eli Lilly	Phase 2	35
Enzastaurin HCl	Eli Lilly	Phase 2	35
Remimazolam Tosilate for Injection	Jiangsu Hengrui Medicine	Pre-clinical	26
ULTRESA + PANCREAZE + CREON + ZENPEP + other non-sponsor pancreatic enzyme replacement therapy + PERTZYE	AbbVie	Pre-clinical	18
Vandetanib + Capecitabine + Oxaliplatin + Bevacizumab	AstraZeneca	Phase 1	29
AZD0292	AstraZeneca	Phase 2	42
Calderasib + Oxaliplatin + Leucovorin/levofolinate calcium + 5-Fluorouracil + Cetuximab + Bevacizumab + Bevacizumab biosimilar	Merck	Phase 3	47
Cetuximab	Merck	Phase 2	27
Entereg + Entereg + placebo	Merck	Phase 2	35
Pembrolizumab	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	27
Pembrolizumab + Ibrutinib	Merck	Phase 1/2	32
pembrolizumab + Poly-ICLC	Merck	Phase 1/2	32
MK-2206	Merck	Phase 2	27